500 related articles for article (PubMed ID: 29084161)
21. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
22. A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH.
Klotsman M; Weinberg CR; Davis K; Binnie CG; Hartmann KE
Pharmacogenomics J; 2004; 4(4):251-9. PubMed ID: 15136785
[TBL] [Abstract][Full Text] [Related]
23. The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH).
Chen ZP; Yan Y; Chen CJ; Li M; Chen C; Zhao SC; Song T; Liu T; Zou CH; Xu Q; Li X
Andrology; 2018 Jul; 6(4):568-578. PubMed ID: 29873201
[TBL] [Abstract][Full Text] [Related]
24. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
[TBL] [Abstract][Full Text] [Related]
25. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
26. Variants in the SRD5A2 gene are associated with quality of semen.
Zhao D; Wu W; Xu B; Niu X; Cui H; Zhang Y; Wang Z; Wang X
Mol Med Rep; 2012 Sep; 6(3):639-44. PubMed ID: 22735779
[TBL] [Abstract][Full Text] [Related]
27. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
Allen NE; Reichardt JK; Nguyen H; Key TJ
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
[TBL] [Abstract][Full Text] [Related]
28. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.
Wang Z; Hu L; Salari K; Bechis SK; Ge R; Wu S; Rassoulian C; Pham J; Wu CL; Tabatabaei S; Strand DW; Olumi AF
J Pathol; 2017 Dec; 243(4):457-467. PubMed ID: 28940538
[TBL] [Abstract][Full Text] [Related]
29. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
30. Combination of Ligustri Lucidi Fructus with Ecliptae Herba and their phytoestrogen or phytoandrogen like active pharmaceutical ingredients alleviate oestrogen/testosterone-induced benign prostatic hyperplasia through regulating steroid 5-α-reductase.
Tao R; Liu E; Zhao X; Han L; Yu B; Mao H; Yang W; Gao X
Phytomedicine; 2022 Jul; 102():154169. PubMed ID: 35636178
[TBL] [Abstract][Full Text] [Related]
31. Extracts of
Song KH; Seo CS; Yang WK; Gu HO; Kim KJ; Kim SH
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33803357
[TBL] [Abstract][Full Text] [Related]
32. Androgenic correlates of genetic variation in the gene encoding 5alpha-reductase type 1.
Ellis JA; Panagiotopoulos S; Akdeniz A; Jerums G; Harrap SB
J Hum Genet; 2005; 50(10):534-537. PubMed ID: 16155734
[TBL] [Abstract][Full Text] [Related]
33. Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia.
Grzesiak K; Rył A; Ratajczak W; Stachowska E; Rotter I; Słojewski M; Sipak O; Walczakiewicz K; Laszczyńska M
Aging (Albany NY); 2019 Mar; 11(5):1524-1536. PubMed ID: 30867336
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; McGree ME; Hebbring SJ; Cunningham JM; Anderson SA; Thibodeau SN; Lieber MM; Jacobsen SJ
Prostate; 2005 Mar; 62(4):380-7. PubMed ID: 15389785
[TBL] [Abstract][Full Text] [Related]
35. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
36. Associations of SRD5A1 gene variants and testosterone with dysglycemia: Henan Rural Cohort study.
Liu X; Wei D; Jiang J; Liu X; Tu R; Luo Z; Wang Y; Dong X; Qiao D; Shen F; Li R; Wang Y; Jin Y; Yu S; Huo W; Li L; Li W; Jing T; Wang C; Mao Z
Nutr Metab Cardiovasc Dis; 2020 Apr; 30(4):599-607. PubMed ID: 31870594
[TBL] [Abstract][Full Text] [Related]
37. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
38. Associations of
Zhang LL; Song Y; He LL; Chen GQ; Fu JC; Liu L; Xi B; Wang L
Int J Clin Exp Pathol; 2017; 10(8):8660-8676. PubMed ID: 31966724
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia.
Liu Z; Lin Z; Cao F; Jiang M; Jin S; Cui Y; Niu YN
BMC Urol; 2022 Nov; 22(1):172. PubMed ID: 36344974
[TBL] [Abstract][Full Text] [Related]
40. Association between
Zeng XT; Su XJ; Li S; Weng H; Liu TZ; Wang XH
Front Physiol; 2017; 8():688. PubMed ID: 28955247
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
